Larsen J J, Hermansen K
Acta Pharmacol Toxicol (Copenh). 1977 Jan;40(1):42-64. doi: 10.1111/j.1600-0773.1977.tb02052.x.
The bronchodilator effect of QH25 (3-(4-methoxybenzylamino)-4-hydroxy-alpha-(tert. butylaminomethyl)benzylalcohol, HCl) a new beta2-adrenergic bronchodilator has been investigated in conscious guinea pigs and in anaesthetized guinea pigs and cats and compared to that of salbutamol and isoprenaline. In anaesthetized guinea pigs QH25 and isoprenaline were equipotent after intravenous administration, whereas salbutamol was four times less active. The same difference between QH25 and salbutamol was observed after intraduodenal administration. After oral administration in conscious guinea pigs QH25 was eight and five times more potent than salbutamol and isoprenaline respectively, whereas no difference was observed when the agents were administered as aerosols. The bronchodilator action of QH25 was apprxomately three times that of salbutamol in egg-albumine sensitized guinea pigs after oral administration. In anaesthetized cats the bronchodilator potency of QH25 was three times that of salbutamol and the same or slightly higher than that of isoprenaline. A half-life of 4 hours for the bronchodilator action in guinea pigs was determined for both QH25 and salbutamol after oral administration. The effect of QH25 and salbutamol on cardiovascular parameters i.e. chrono- and inotropic action and blood pressure decreasing effect in guinea pigs, cats and dogs was essentially the same whereas isoprenaline was from 5 to 30 times more potent. The potential tremorogenic action of QH25 estimated on the cat soleus muscle was eight times less than that of isoprenaline and the same or slightly less than that of salbutamol. From the experimental data it is concluded that QH25 has the same potency as isoprenaline as a bronchodilator agent but is more potent than salbutamol. Taking into account that isoprenaline is considerably more active on cardiovascular parameters and on the cat soleus muscle than QH25 which has the same or less effect than salbutamol on these parameters the data suggest that QH25 is a more selective bronchodilator agent than both isoprenaline and salbutamol.
新型β2 - 肾上腺素能支气管扩张剂QH25(3 - (4 - 甲氧基苄氨基) - 4 - 羟基 - α - (叔丁氨基甲基)苄醇,盐酸盐)的支气管扩张作用已在清醒豚鼠、麻醉豚鼠和猫身上进行了研究,并与沙丁胺醇和异丙肾上腺素进行了比较。在麻醉豚鼠中,静脉注射后QH25和异丙肾上腺素的效力相当,而沙丁胺醇的活性则低四倍。十二指肠给药后,QH25和沙丁胺醇之间也观察到同样的差异。在清醒豚鼠口服给药后,QH25的效力分别比沙丁胺醇和异丙肾上腺素强八倍和五倍,而当以气雾剂形式给药时,未观察到差异。口服给药后,在卵清蛋白致敏的豚鼠中,QH25的支气管扩张作用约为沙丁胺醇的三倍。在麻醉猫中,QH25的支气管扩张效力是沙丁胺醇的三倍,与异丙肾上腺素相同或略高。口服给药后,豚鼠体内QH25和沙丁胺醇的支气管扩张作用半衰期均为4小时。QH25和沙丁胺醇对豚鼠、猫和狗的心血管参数(即变时和变力作用以及血压降低作用)的影响基本相同,而异丙肾上腺素的效力则强5至30倍。根据猫比目鱼肌评估,QH25的潜在致震颤作用比异丙肾上腺素小八倍,与沙丁胺醇相同或略小。从实验数据得出的结论是,QH25作为支气管扩张剂与异丙肾上腺素效力相同,但比沙丁胺醇更有效。考虑到异丙肾上腺素在心血管参数和猫比目鱼肌上的活性比QH25高得多,而QH25在这些参数上的作用与沙丁胺醇相同或更小,数据表明QH25是一种比异丙肾上腺素和沙丁胺醇更具选择性的支气管扩张剂。